Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.39 |
| ▸ | ITGAL | P20701 | 4/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585610 | 0.81 | ADRB2 (0.53) | ADRB2PRMT5CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL5585742 | 0.78 | HTR6 (0.52) | ADRB2PRMT5CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL5585826 | 0.77 | ADRB2 (0.49) | ADRB2PRMT5CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL3266751 | 0.75 | HTR2C (0.64) | CYP1A2CYP2C19CYP2C9HTR2CADRB1 | |
| SCHEMBL5585242 | 0.75 | ADRB2 (0.49) | ADRB2PRMT5CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL5585730 | 0.75 | ADRB2 (0.51) | ADRB2PRMT5CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL5585313 | 0.74 | ADRB2 (0.55) | ADRB2PRMT5CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL5585592 | 0.73 | PRMT5 (0.58) | ADRB2PRMT5CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL5585578 | 0.73 | ADRB2 (0.46) | ADRB2PRMT5CYP1A2CYP2C9HTR2C | |
| SCHEMBL6185077 | 0.72 | ADRB2 (0.51) | ADRB2PRMT5CYP1A2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | claimed |
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | claimed |
| CN-1701068-A | Novel compounds and their use | BIOVITRUM AB (SE) | 2005-11-23 | — | — | CN | claimed |
| JP-2005529926-A | — | — | 2005-10-06 | — | — | JP | claimed |
| EP-1506185-A1 | NOVEL COMPOUNDS AND THEIR USE | Biovitrum AB (SE) | 2005-02-16 | — | — | EP | claimed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | claimed |
| WO-2003097636-A1 | NOVEL COMPOUNDS AND THEIR USE | BIOVITRUM AB (SE) | 2003-11-27 | — | — | WO | claimed |
| US-7229997-B2 | Compounds and their use | BIOVITRUM AB (SE) | 2007-06-12 | — | — | US | disclosed |
| EP-1506185-B1 | COMPOUNDS AND THEIR USE AS INHIBITORS OF 5-HT | BIOVITRUM AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| CN-1701068-A | Novel compounds and their use | BIOVITRUM AB (SE) | 2005-11-23 | — | — | CN | disclosed |
| EP-1506185-A1 | NOVEL COMPOUNDS AND THEIR USE | Biovitrum AB (SE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030232814-A1 | Novel compounds and their use | BIOVITRUM AB (PUBL) (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003097636-A1 | NOVEL COMPOUNDS AND THEIR USE | BIOVITRUM AB (SE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232814-A1 | Novel compounds and their use | GPR119, FABP4, MC4R | ADRB2 63/4885PRMT5 974/4885LMNA 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.